Lesley J. Millatt

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Bart Staels, A. Rubenstrunk, Benoît Noël et al. · Hepatology · 2013 · 402 citations

ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver

Pierre‐Damien Denechaud, Pascale Bossard, Jean‐Marc A. Lobaccaro et al. · Journal of Clinical Investigation · 2008 · 193 citations · Full text

Evidence for Dysregulation of Dimethylarginine Dimethylaminohydrolase I in Chronic Hypoxia–Induced Pulmonary Hypertension

Lesley J. Millatt, Guy Whitley, Dechun Li et al. · Circulation · 2003 · 123 citations

Acute Lung Injury, Hypertension, Inflammatory Lung Disease +20

Differential Regulation of Renal Angiotensin Subtype AT _1A and AT ₂ Receptor Protein in Rats With Angiotensin-Dependent Hypertension

Zhi-Qin Wang, Lesley J. Millatt, Nicholas T. Heiderstadt et al. · Hypertension · 1999 · 93 citations

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in <i>db</i>/<i>db</i> mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects

Rémy Hanf, Lesley J. Millatt, Bertrand Cariou et al. · Diabetes and Vascular Disease Research · 2014 · 36 citations · Full text

Anti-diabetic Effects, Cardiometabolic Risk, Cardiovascular Pharmacology +23